Capital Fund Management (CFM)
SMMT icon

Capital Fund Management (CFM)’s Summit Therapeutics SMMT Stock Holding History

Capital Fund Management (CFM)’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$216K Buy
+11,400
New +$184K ﹤0.01% 1998

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Capital Fund Management (CFM)'s SMMT Position: Q1 2026 in Review

Capital Fund Management (CFM) sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 113,391 shares — an estimated $1.83M sold.

Capital Fund Management (CFM) first reported a position in SMMT in Q3 2024 and held it in 3 quarters. The position peaked at $1.98M in Q4 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Capital Fund Management (CFM) reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 113,391 Summit Therapeutics shares in Q1 2026, an estimated $1.83M.
  • Capital Fund Management (CFM) first reported a position in Summit Therapeutics in Q3 2024 and held it in 3 quarters.
  • Capital Fund Management (CFM)'s Summit Therapeutics position peaked at $1.98M in Q4 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.